Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled …

G Meyer, Z Marjanovic, J Valcke… - Archives of internal …, 2002 - jamanetwork.com
Background The use of warfarin sodium for treating venous thromboembolism in patients
with cancer is associated with a significant risk of recurrence and bleeding. The use of low-…

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

…, D Farge, JK Sont, K Naraghi, Z Marjanovic… - Jama, 2014 - jamanetwork.com
Importance High-dose immunosuppressive therapy and autologous hematopoietic stem cell
transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small …

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

…, A Makatsariya, A Maneyro, Z Marjanovic… - The Lancet …, 2022 - thelancet.com
The International Initiative on Thrombosis and Cancer is an independent academic working
group of experts aimed at establishing global consensus for the treatment and prophylaxis of …

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

…, M Mandala, A Marayevas, Z Marjanovic… - The Lancet …, 2019 - thelancet.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer.
These patients are at a high risk of VTE recurrence and bleeding during anticoagulant …

[HTML][HTML] Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

…, S Sestilli, A Vekhof, E Brissot, Z Marjanovic… - Blood cancer …, 2021 - nature.com
This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with
hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) …

[HTML][HTML] COVID-19 outcomes in patients with hematologic disease

…, E Brissot, Z van de Wyngaert, Z Marjanovic… - Bone Marrow …, 2020 - nature.com
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus of
zoonotic origin that emerged in China at the end of 2019. The infection, named Coronavirus …

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study b the Société Française de Greffe de Moelle et de Thérapie …

…, A Schmidt-Tanguy, Z Marjanovic… - Journal of clinical …, 2012 - orbi.uliege.be
Purpose : To investigate the impact of prior-to-transplantation azacitidine (AZA) on patient
outcome after allogeneic stem-cell transplantation (alloSCT) for myelodysplastic syndrome (…

Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis

MC Vonk, Z Marjanovic, FHJ van den Hoogen… - Annals of the …, 2008 - ard.bmj.com
Objective: Systemic sclerosis (SSc) is a generalised autoimmune disease, causing morbidity
and a reduced life expectancy, especially in patients with rapidly progressive diffuse …

Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases

…, M Labopin, S Giebel, E McGrath, Z Marjanovic… - Blood …, 2017 - ashpublications.org
Hematopoietic stem cell transplantation (HSCT) has evolved for >20 years as a specific
treatment of patients with autoimmune disease (AD). Using European Society for Blood and …

Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for …

…, E Ruderman, D Farge, ZJ Chai, Z Marjanovic… - The Lancet, 2013 - thelancet.com
Background Autologous haemopoietic stem-cell transplantation (HSCT) benefits patients with
systemic sclerosis but has been associated with significant treatment-related mortality and …